menu
    • menu

    Company profile for Kitov Pharma

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov’s oncology pipeline includes NT-219 and CM-24.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kitov PharmaIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    One Azrieli Center Round Tower, Floor 19 132 Menachem Begin Road Tel Aviv 6701...
    Telephone
    Telephone
    972 3 9333121
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://purple-biotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kitov Expands Planned Phase 1/2 Trial of CM24 in Non-Small Cell Lung Cancer
    Kitov Expands Planned Phase 1/2 Trial of CM24 in Non-Small Cell Lung Cancer

    09 Nov 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/11/09/2122659/0/en/Kitov-Expands-Planned-Phase-1-2-Clinical-Trial-of-CM24-in-Non-Small-Cell-Lung-Cancer-with-New-Cohort-to-Evaluate-CM24-in-Patients-with-Pancreatic-Cancer-Conducted-with-Bristol-Myer.html

    GLOBENEWSWIRE
    09 Nov 2020
    Share Share
    Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219
    Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219

    09 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/09/2059866/0/en/Kitov-Announces-Initiation-of-Phase-1-2-Clinical-Trial-of-NT219-in-Advanced-Cancer-Patients.html

    GLOBENEWSWIRE
    09 Jul 2020
    Share Share
    Kitov Receives Notice of Intention to Grant a European Patent Covering CM24
    Kitov Receives Notice of Intention to Grant a European Patent Covering CM24

    08 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/08/2059185/0/en/kitov-pharma-receives-notice-of-intention-to-grant-a-european-patent-covering-cm24-its-anti-ceacam1-antibody.html

    GLOBENEWSWIRE
    08 Jul 2020
    Share Share
    Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
    Kitov Pharma Issues CEO Shareholder Letter Providing Business Update

    02 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/02/2056925/0/en/Kitov-Pharma-Issues-CEO-Shareholder-Letter-Providing-Business-Update.html

    GLOBENEWSWIRE
    02 Jul 2020
    Share Share
    Kitov Announces U.S. FDA Acceptance of INDA to Conduct Ph 1/2 Trial of NT219
    Kitov Announces U.S. FDA Acceptance of INDA to Conduct Ph 1/2 Trial of NT219

    22 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/22/2037517/0/en/Kitov-Announces-U-S-FDA-Acceptance-of-Investigational-New-Drug-Application-to-Conduct-Phase-1-2-Clinical-Trial-of-NT219-in-Multiple-Types-of-Advanced-Cancer-Patients.html

    GLOBENEWSWIRE
    22 May 2020
    Share Share
    Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 M from Exercise of Warrants
    Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 M from Exercise of Warrants

    20 Apr 2020

    // YAHOO

    https://finance.yahoo.com/news/kitov-pharma-ltd-announces-cash-120510763.html

    YAHOO
    20 Apr 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search